Ahn-Gook Pharmaceutical Co. Ltd (001540) - Total Liabilities
Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) has total liabilities worth ₩136.13 Billion KRW (≈ $92.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 001540 cash flow metrics to assess how effectively this company generates cash.
Ahn-Gook Pharmaceutical Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Ahn-Gook Pharmaceutical Co. Ltd (001540) asset resilience to evaluate the company's liquid asset resilience ratio.
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Ahn-Gook Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Everbrite Technology Co Ltd
TWO:4523
|
Taiwan | NT$2.22 Billion |
|
AmeriServ Financial Inc
NASDAQ:ASRV
|
USA | $1.34 Billion |
|
Unick Corporation
KQ:011320
|
Korea | ₩160.10 Billion |
|
Chegg Inc
NYSE:CHGG
|
USA | $157.20 Million |
|
Scherzer & Co. AG
F:PZS
|
Germany | €8.01 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
Norcod As
OL:NCOD
|
Norway | Nkr335.97 Million |
|
Cobre Ltd
AU:CBE
|
Australia | AU$6.80 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Ahn-Gook Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 001540 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ahn-Gook Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual total liabilities of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩136.86 Billion ≈ $92.75 Million |
+57.43% |
| 2023-12-31 | ₩86.93 Billion ≈ $58.91 Million |
+25.78% |
| 2022-12-31 | ₩69.11 Billion ≈ $46.84 Million |
+3.88% |
| 2021-12-31 | ₩66.54 Billion ≈ $45.09 Million |
+15.51% |
| 2020-12-31 | ₩57.60 Billion ≈ $39.04 Million |
-17.37% |
| 2019-12-31 | ₩69.71 Billion ≈ $47.24 Million |
+5.37% |
| 2018-12-31 | ₩66.16 Billion ≈ $44.83 Million |
-6.96% |
| 2017-12-31 | ₩71.11 Billion ≈ $48.19 Million |
+8.77% |
| 2016-12-31 | ₩65.37 Billion ≈ $44.30 Million |
-2.12% |
| 2015-12-31 | ₩66.79 Billion ≈ $45.26 Million |
+18.00% |
| 2014-12-31 | ₩56.61 Billion ≈ $38.36 Million |
+53.74% |
| 2013-12-31 | ₩36.82 Billion ≈ $24.95 Million |
-31.14% |
| 2012-12-31 | ₩53.47 Billion ≈ $36.24 Million |
+3.29% |
| 2011-12-31 | ₩51.77 Billion ≈ $35.08 Million |
-- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.